Paige L Williams1, Cenk Yildirim2, Ellen G Chadwick3, Russell B Van Dyke4, Renee Smith5, Katharine F Correia6, Alexandria DiPerna7, George R Seage2, Rohan Hazra8, Claudia S Crowell9. 1. Center for Biostatistics in AIDS Research, Harvard T H Chan School of Public Health, Boston, MA, USA. Electronic address: paige@hsph.harvard.edu. 2. Center for Biostatistics in AIDS Research, Harvard T H Chan School of Public Health, Boston, MA, USA. 3. Northwestern University Feinberg School of Medicine, Chicago, IL, USA. 4. Tulane University School of Medicine, New Orleans, LA, USA. 5. University of Illinois at Chicago, Chicago, IL, USA. 6. Amherst College, Amherst, MA, USA. 7. Frontier Science Technology and Research Foundation, Amherst, NY, USA. 8. Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD, USA. 9. Seattle Children's Hospital and University of Washington, Seattle, WA, USA.
Abstract
BACKGROUND: Perinatal HIV transmission has substantially decreased with combination antiretroviral regimens, but complications in children who are HIV-exposed but uninfected, such as microcephaly, warrant ongoing surveillance. We aimed to evaluate whether individual in utero antiretroviral exposures were associated with increased risk of microcephaly based on long-term follow-up of infants and children who are HIV-exposed but uninfected. METHODS: We evaluated children aged younger than 18 years who were HIV-exposed but uninfected with at least one head circumference measurement while enrolled in the Surveillance Monitoring for ART Toxicities (SMARTT) study at 22 clinical sites in the USA, including Puerto Rico. This prospective cohort study was done by the Pediatric HIV/AIDS Cohort Study network. Microcephaly was defined as having a head circumference Z score <-2 according to the 2000 US Centers for Disease Control and Prevention growth charts for children 6-36 months old and according to Nellhaus standards (head circumference <2nd percentile) after 36 months (SMARTT criteria); an alternate definition for microcephaly was based on applying Nellhaus standards across all ages (Nellhaus criteria). Modified Poisson regression models were fit to obtain relative risks (RRs) for associations between in utero antiretroviral exposure and microcephaly status, adjusted for potential confounders. Neurodevelopmental functioning was compared in children who are HIV-exposed but uninfected with or without microcephaly. FINDINGS: Between March 21, 2007, and Aug 1, 2017, 3055 participants enrolled in SMARTT had at least one head circumference measurement. The cumulative incidence of microcephaly over a median of 5·1 years of follow-up (IQR 3·0-7·2) was 159 (5·2%, 95% CI 4·4-6·1) by Nellhaus criteria and 70 (2·3%, 1·8-2·9) by SMARTT criteria. In adjusted models, in utero exposure to efavirenz (4·7% exposed) was associated with increased risk of microcephaly by both Nellhaus standards (adjusted RR 2·02, 95% CI 1·16-3·51) and SMARTT criteria (2·56, 1·22-5·37). These associations were more pronounced in children exposed to combination regimens of efavirenz that included zidovudine plus lamivudine than those including tenofovir plus emtricitabine. Protective associations were observed for darunavir exposure (adjusted RR 0·50, 95% CI 0·24-1·00). Children who are HIV-exposed but uninfected with microcephaly had lower mean scores on neurodevelopmental assessments at age 1 and 5 years and a higher prevalence of neurodevelopmental impairment than those without microcephaly. INTERPRETATION: These findings support consideration of alternatives to efavirenz as part of first-line antiretroviral therapy for pregnant women. FUNDING: Eunice Kennedy Shriver National Institute of Child Health and Human Development.
BACKGROUND: Perinatal HIV transmission has substantially decreased with combination antiretroviral regimens, but complications in children who are HIV-exposed but uninfected, such as microcephaly, warrant ongoing surveillance. We aimed to evaluate whether individual in utero antiretroviral exposures were associated with increased risk of microcephaly based on long-term follow-up of infants and children who are HIV-exposed but uninfected. METHODS: We evaluated children aged younger than 18 years who were HIV-exposed but uninfected with at least one head circumference measurement while enrolled in the Surveillance Monitoring for ART Toxicities (SMARTT) study at 22 clinical sites in the USA, including Puerto Rico. This prospective cohort study was done by the Pediatric HIV/AIDS Cohort Study network. Microcephaly was defined as having a head circumference Z score <-2 according to the 2000 US Centers for Disease Control and Prevention growth charts for children 6-36 months old and according to Nellhaus standards (head circumference <2nd percentile) after 36 months (SMARTT criteria); an alternate definition for microcephaly was based on applying Nellhaus standards across all ages (Nellhaus criteria). Modified Poisson regression models were fit to obtain relative risks (RRs) for associations between in utero antiretroviral exposure and microcephaly status, adjusted for potential confounders. Neurodevelopmental functioning was compared in children who are HIV-exposed but uninfected with or without microcephaly. FINDINGS: Between March 21, 2007, and Aug 1, 2017, 3055 participants enrolled in SMARTT had at least one head circumference measurement. The cumulative incidence of microcephaly over a median of 5·1 years of follow-up (IQR 3·0-7·2) was 159 (5·2%, 95% CI 4·4-6·1) by Nellhaus criteria and 70 (2·3%, 1·8-2·9) by SMARTT criteria. In adjusted models, in utero exposure to efavirenz (4·7% exposed) was associated with increased risk of microcephaly by both Nellhaus standards (adjusted RR 2·02, 95% CI 1·16-3·51) and SMARTT criteria (2·56, 1·22-5·37). These associations were more pronounced in children exposed to combination regimens of efavirenz that included zidovudine plus lamivudine than those including tenofovir plus emtricitabine. Protective associations were observed for darunavir exposure (adjusted RR 0·50, 95% CI 0·24-1·00). Children who are HIV-exposed but uninfected with microcephaly had lower mean scores on neurodevelopmental assessments at age 1 and 5 years and a higher prevalence of neurodevelopmental impairment than those without microcephaly. INTERPRETATION: These findings support consideration of alternatives to efavirenz as part of first-line antiretroviral therapy for pregnant women. FUNDING: Eunice Kennedy Shriver National Institute of Child Health and Human Development.
Authors: Caitlin M Dugdale; Andrea L Ciaranello; Linda-Gail Bekker; Madeline E Stern; Landon Myer; Robin Wood; Paul E Sax; Elaine J Abrams; Kenneth A Freedberg; Rochelle P Walensky Journal: Ann Intern Med Date: 2019-04-02 Impact factor: 25.391
Authors: N Paul Rosman; Daniel C Tarquinio; Marianna Datseris; Wei Hou; Glenn B Mannheim; Christie E Emigh; Michael J Rivkin Journal: Pediatrics Date: 2011-03-21 Impact factor: 7.124
Authors: C Macmillan; L S Magder; P Brouwers; C Chase; J Hittelman; T Lasky; K Malee; C A Mellins; J Velez-Borras Journal: Neurology Date: 2001-10-23 Impact factor: 9.910
Authors: Paige L Williams; George R Seage; Russell B Van Dyke; George K Siberry; Raymond Griner; Katherine Tassiopoulos; Cenk Yildirim; Jennifer S Read; Yanling Huo; Rohan Hazra; Denise L Jacobson; Lynne M Mofenson; Kenneth Rich Journal: Am J Epidemiol Date: 2012-04-06 Impact factor: 4.897
Authors: Jeanie L Y Cheong; Rod W Hunt; Peter J Anderson; Kelly Howard; Deanne K Thompson; Hong X Wang; Merilyn J Bear; Terrie E Inder; Lex W Doyle Journal: Pediatrics Date: 2008-06 Impact factor: 7.124
Authors: Babette S Zemel; Mary Pipan; Virginia A Stallings; Waynitra Hall; Kim Schadt; David S Freedman; Phoebe Thorpe Journal: Pediatrics Date: 2015-11 Impact factor: 7.124
Authors: Lisa van de Wijer; Lidiane P Garcia; Sabrina I Hanswijk; Juliette Rando; Anthonieke Middelman; Rob Ter Heine; Quirijn de Mast; Gerard J M Martens; André J A M van der Ven; Sharon M Kolk; Arnt F A Schellekens; Judith R Homberg Journal: Transl Psychiatry Date: 2019-02-11 Impact factor: 6.222
Authors: Catherine J Wedderburn; Ella Weldon; Cesc Bertran-Cobo; Andrea M Rehman; Dan J Stein; Diana M Gibb; Shunmay Yeung; Andrew J Prendergast; Kirsten A Donald Journal: Lancet Child Adolesc Health Date: 2022-04-26